Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

María de los Dolores Fenor de la Maza

Has grant

Clinical Scientist

Vall d'Hebron Institute of Oncology

Spain

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in Spain Professors in Cell Biology Cell Biology professors in Spain

Recent Grants

Grant: Close

Targeting myeloid-derived suppressor cells (MDSCs), and their production of IL-23, to reverse abiraterone resistance in advanced prostate cancer

Open Date:

Close Date:

Articles (12)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Collaborators (9)

Alec Paschalis

Institute of Cancer Research

UNITED KINGDOM

View details

David Olmos Hidalgo

Group leader, distinguished investigator

Instituto de Investigación Hospital 12 de Octubre

SPAIN

View details

Adam Sharp

Team Leader

Institute of Cancer Research

UNITED KINGDOM

View details

ELENA PRIETO

Clinica Universidad de Navarra

SPAIN

View details

Emma Hall

Institute of Cancer Research

UNITED KINGDOM

View details

Mahtab Rouhifard

Institute of Cancer Research

UNITED KINGDOM

View details

Michael Shen

Columbia University Irving Medical Center

UNITED STATES

View details

Andrea Alimonti

Full Professor of Oncology

ETH Zürich

SWITZERLAND

View details

Crescens Diane Tiu

Clinical Scientist

Institute of Cancer Research

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

María de los Dolores Fenor de la Maza

Research Interests

Make your next move.

Explore related searches

Recent Grants

Articles (12)

Association of [68Ga]Ga-PSMA-11 PET/CT Metrics with PSA Persistence Following Radical Prostatectomy in Patients with Intermediate- and High-Risk Prostate Cancer

PERSEUS1: An Open-label, Investigator-initiated, Single arm, Phase 2 Trial Testing the Efficacy of Pembrolizumab in Patients with Metastatic Castration-resistant Prostate Cancer with Mismatch Repair Deficiency and Other Immune-sensitive Molecular Subtypes.

RNASEH2B loss and PARP inhibition in advanced prostate cancer

Immunome profiling in prostate cancer: a guide for clinicians

BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity

PARP inhibitors alone or in combination for prostate cancer

First-line Management of Metastatic Urothelial Cancer: Current and Future Perspectives After the EV-302 and CheckMate-901 Studies

Phase II trial of pembrolizumab for patients suffering from metastatic castration resistant prostate cancer (mCRPC) with DNA repair defects, high tumour mutation burden, and/or high CD3 counts (PERSEUS1).

Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance

Development and Validation of a New BAG-1L–Specific Antibody to Quantify BAG-1L Protein Expression in Advanced Prostate Cancer

Germline ATM Mutations Detected by Somatic DNA Sequencing in Lethal Prostate Cancer

B7-H3 as a Therapeutic Target in Advanced Prostate Cancer

Collaborators (9)

Alec Paschalis

David Olmos Hidalgo

Adam Sharp

ELENA PRIETO

Emma Hall

Mahtab Rouhifard

Michael Shen

Andrea Alimonti

Crescens Diane Tiu

Make your next move.